Compare · ICCC vs IDXX
ICCC vs IDXX
Side-by-side comparison of ImmuCell Corporation (ICCC) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $41.47B, about 664.6x ICCC ($62.4M).
- Over the past year, ICCC is up 52.5% and IDXX is up 30.5% - ICCC leads by 22.1 points.
- ICCC has been more active in the news (18 items in the past 4 weeks vs 2 for IDXX).
- IDXX has more recent analyst coverage (23 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- IDEXX Laboratories Inc.
- Price
- $8.39+8.96%
- $565.97+0.89%
- Market cap
- $62.4M
- $41.47B
- 1M return
- +31.50%
- -1.66%
- 1Y return
- +52.55%
- +30.49%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- 1991
- News (4w)
- 18
- 2
- Recent ratings
- 0
- 23
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest ICCC
- SEC Form DEF 14A filed by ImmuCell Corporation
- SEC Form 3 filed by new insider Dimarco Anthony
- SEC Form 3 filed by new insider Guillemette Gilles
- SEC Form 4 filed by Turner Kathy V
- SEC Form 4 filed by Tomsche David Scott
- SEC Form 4 filed by Basse Gloria F
- SEC Form 4 filed by Wainman Paul R
- SEC Form PRE 14A filed by ImmuCell Corporation
- SEC Form 4 filed by Gathagan Bryan K.
- SEC Form 4 filed by Wainman Paul R
Latest IDXX
- Citigroup initiated coverage on IDEXX Labs with a new price target
- IDEXX Laboratories to Release 2026 First Quarter Financial Results
- IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
- SEC Form DEFA14A filed by IDEXX Laboratories Inc.
- SEC Form DEF 14A filed by IDEXX Laboratories Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form PRE 14A filed by IDEXX Laboratories Inc.
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 197 shares at a strike of $505.53, increasing direct ownership by 3% to 7,138 units (SEC Form 4)
- Executive Vice President Hunt Nimrata sold $1,115,577 worth of shares (1,758 units at $634.57), decreasing direct ownership by 9% to 18,141 units (SEC Form 4)